{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:14:38Z","timestamp":1778069678309,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hellenic Journal of Cardiology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.hjc.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:59:00Z","timestamp":1776383940000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of hematologic cancer with characteristics, causes, and outcomes of patients with cardiovascular admissions"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7031-8628","authenticated-orcid":false,"given":"Moksh Sanjay","family":"Khetan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrija","family":"Matetic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timir K.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Golam","family":"Azam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankur","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamas A.","family":"Mamas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hjc.2026.04.001_bib1","series-title":"Cancer Facts & Figures 2020","year":"2020"},{"issue":"4","key":"10.1016\/j.hjc.2026.04.001_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1053\/j.seminoncol.2015.05.003","article-title":"Cancer and the immune system: basic concepts and targets for intervention","volume":"42","author":"Pardoll","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hjc.2026.04.001_bib3","series-title":"Cardiovascular Diseases (CVDs)","year":"2021"},{"issue":"2","key":"10.1016\/j.hjc.2026.04.001_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/ejh.13983","article-title":"Cardiovascular risk in chronic myeloid leukaemia: a multidisciplinary consensus on screening and management","volume":"111","author":"Milojkovic","year":"2023","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.hjc.2026.04.001_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"165","author":"Dahl\u00e9n","year":"2016","journal-title":"Ann Intern Med"},{"issue":"24","key":"10.1016\/j.hjc.2026.04.001_bib6","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hjc.2026.04.001_bib7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.amjcard.2023.11.039","article-title":"Cardiovascular risk in patients with hematological malignancies: a systematic review and meta-analysis","volume":"212","author":"Yong","year":"2024","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.hjc.2026.04.001_bib8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","article-title":"Epidemiology and aetiology of heart failure","volume":"13","author":"Ziaeian","year":"2016","journal-title":"Nat Rev Cardiol"},{"issue":"48","key":"10.1016\/j.hjc.2026.04.001_bib9","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hjc.2026.04.001_bib10","doi-asserted-by":"crossref","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines","volume":"23","author":"Curigliano","year":"2012","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.hjc.2026.04.001_bib11","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the Task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hjc.2026.04.001_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijcard.2021.07.054","article-title":"Impact of cancer diagnosis on causes and outcomes of 5.9 million US patients with cardiovascular admissions","volume":"341","author":"Matetic","year":"2021","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.hjc.2026.04.001_bib13","first-page":"639","article-title":"Treatment of patients with myocardial infarction depends on history of cancer","volume":"7","author":"Rohrmann","year":"2018","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"4","key":"10.1016\/j.hjc.2026.04.001_bib14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/ehf2.12450","article-title":"Health care utilization and mortality associated with heart failure-related admissions among cancer patients","volume":"6","author":"Guha","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hjc.2026.04.001_bib15","series-title":"Healthcare Cost and Utilization Project (HCUP)","year":"2012"},{"issue":"4","key":"10.1016\/j.hjc.2026.04.001_bib16","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.athoracsur.2020.06.033","article-title":"Impact of hematologic malignancies on outcome of cardiac surgery","volume":"111","author":"Nguyen","year":"2021","journal-title":"Ann Thorac Surg"},{"issue":"21","key":"10.1016\/j.hjc.2026.04.001_bib17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood.V124.21.1149.1149","article-title":"CARDIOVASCULAR and metabolic complications in patients with hematological malignancies undergoing allogeneic hematopoietic STEM CELL transplantation (HSCT)","volume":"124","author":"Arboscello","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hjc.2026.04.001_bib18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11906-007-0058-7","article-title":"Chemotherapy agents and hypertension: a focus on angiogenesis blockade","volume":"9","author":"Jain","year":"2007","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"10.1016\/j.hjc.2026.04.001_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: cardiooncology state-of-the-art review","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC CardioOncology"},{"key":"10.1016\/j.hjc.2026.04.001_bib20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.blre.2019.03.003","article-title":"Hypertension in hematologic malignancies and hematopoietic cell transplantation: an emerging issue with the introduction of novel treatments","volume":"35","author":"Gavriilaki","year":"2019","journal-title":"Blood Rev"},{"issue":"12","key":"10.1016\/j.hjc.2026.04.001_bib21","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","article-title":"Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia","volume":"23","author":"Lipshultz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hjc.2026.04.001_bib22","first-page":"e46","article-title":"Cancer therapy-related hypertension: a scientific statement from the American heart association","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertens Dallas Tex 1979"},{"issue":"3","key":"10.1016\/j.hjc.2026.04.001_bib23","first-page":"263","article-title":"Hypertension in cancer patients","volume":"38","author":"Mouhayar","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.hjc.2026.04.001_bib24","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.hjc.2026.04.001_bib25","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.3324\/haematol.2019.235804","article-title":"New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity","volume":"105","author":"Elhammali","year":"2020","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.hjc.2026.04.001_bib26","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/bloodadvances.2019030858","article-title":"Low-dose radiation (4 Gy) with\/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma","volume":"3","author":"Ning","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.hjc.2026.04.001_bib27","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hjc.2026.04.001_bib28","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/jth.14475","article-title":"Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study","volume":"17","author":"Adelborg","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.hjc.2026.04.001_bib29","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/HCO.0000000000000641","article-title":"Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy","volume":"34","author":"Zarifa","year":"2019","journal-title":"Curr Opin Cardiol"},{"issue":"4","key":"10.1016\/j.hjc.2026.04.001_bib30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clml.2019.12.027","article-title":"Cardiotoxicity in hematopoietic stem cell transplant: keeping the beat","volume":"20","author":"Baker","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"47","key":"10.1016\/j.hjc.2026.04.001_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027921","article-title":"Associations of cardiovascular risk factors with survival outcomes in a cancer registration: findings from the KUMAMON registry","volume":"100","author":"Maki","year":"2021","journal-title":"Medicine (Baltim)"},{"issue":"Suppl_1","key":"10.1016\/j.hjc.2026.04.001_bib32","doi-asserted-by":"crossref","first-page":"A9784","DOI":"10.1161\/circ.146.suppl_1.9784","article-title":"Abstract 9784: all-cause mortality and cardiovascular events in cancer patients undergoing hematopoietic stem cell transplantation (Kurume-CREO Study)","volume":"146","author":"Morikawa","year":"2022","journal-title":"Circulation"}],"container-title":["Hellenic Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966626000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966626000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:35:11Z","timestamp":1778067311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1109966626000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"alternative-id":["S1109966626000795"],"URL":"https:\/\/doi.org\/10.1016\/j.hjc.2026.04.001","relation":{},"ISSN":["1109-9666"],"issn-type":[{"value":"1109-9666","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of hematologic cancer with characteristics, causes, and outcomes of patients with cardiovascular admissions","name":"articletitle","label":"Article Title"},{"value":"Hellenic Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hjc.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Hellenic Society of Cardiology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}